These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10073791)

  • 1. Effect of niacin and etofibrate association on subjects with coronary artery disease and serum high-density lipoprotein cholesterol <35 mg/dl.
    Spósito AC; Caramelli B; Serrano CV; Mansur AP; Ramires JA
    Am J Cardiol; 1999 Jan; 83(1):98-100, A8. PubMed ID: 10073791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects.
    Sposito AC; Mansur AP; Maranhão RC; Rodrigues-Sobrinho CR; Coelho OR; Ramires JA
    Braz J Med Biol Res; 2001 Feb; 34(2):177-82. PubMed ID: 11175492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease.
    Spósito AC; Maranhão RC; Vinagre CG; Santos RD; Ramires JA
    Atherosclerosis; 2001 Feb; 154(2):455-61. PubMed ID: 11166779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
    Li XP; Duan J; Zhao SP; Tan MY; Xu ZM; Zhang DQ
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2399-403. PubMed ID: 17156651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
    Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
    J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
    Mertz DP; Loewer H; Suermann I
    Med Klin; 1979 Dec; 74(51-52):1953-6. PubMed ID: 542179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease.
    Lavie CJ; Mailander L; Milani RV
    Am J Cardiol; 1992 Apr; 69(12):1083-5. PubMed ID: 1561983
    [No Abstract]   [Full Text] [Related]  

  • 8. Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol.
    Toth PP; Zarotsky V; Sullivan JM; Laitinen D
    Curr Med Res Opin; 2009 Jun; 25(6):1355-63. PubMed ID: 19425901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ
    J Am Coll Cardiol; 2010 Jun; 55(24):2721-6. PubMed ID: 20399059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvastatin with and without niacin for hypercholesterolemia.
    Jacobson TA; Chin MM; Fromell GJ; Jokubaitis LA; Amorosa LF
    Am J Cardiol; 1994 Jul; 74(2):149-54. PubMed ID: 8023779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio.
    Alderman JD; Pasternak RC; Sacks FM; Smith HS; Monrad ES; Grossman W
    Am J Cardiol; 1989 Oct; 64(12):725-9. PubMed ID: 2801522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of etofibrate on low density lipoprotein metabolism.
    Series JJ; Caslake MJ; Kilday C; Cruickshank A; Demant T; Packard CJ; Shepherd J
    Atherosclerosis; 1988 Feb; 69(2-3):233-9. PubMed ID: 3348843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
    Kastelein JJ
    Am J Cardiol; 2005 Nov; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin therapy with ezetimibe or niacin in high-risk patients.
    Kastelein JJ; Bots ML
    N Engl J Med; 2009 Nov; 361(22):2180-3. PubMed ID: 19915218
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
    Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
    Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials.
    Taylor AJ
    Am J Cardiol; 2008 Apr; 101(8A):36B-43B. PubMed ID: 18375240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.
    Taylor AJ; Sullenberger LE; Lee HJ; Lee JK; Grace KA
    Circulation; 2004 Dec; 110(23):3512-7. PubMed ID: 15537681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.
    Dubé MP; Komarow L; Fichtenbaum CJ; Cadden JJ; Overton ET; Hodis HN; Currier JS; Stein JH;
    Clin Infect Dis; 2015 Sep; 61(5):840-9. PubMed ID: 25979307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etofibrate therapy and effect of added low-dose cholestyramine in patients with combined hyperlipidaemia.
    Krüger B
    Int J Clin Pharmacol Res; 1994; 14(5-6):177-83. PubMed ID: 7672874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.